Literature DB >> 15365106

To control and beyond: moving towards eliminating the global tuberculosis threat.

Timothy F Brewer1, S Jody Heymann.   

Abstract

For 10 years the World Health Organisation has had a single answer to the deadly threat of tuberculosis (TB)-provide treatment to smear positive patients and watch them take it. In contrast with confident statements about how global TB would be brought under control when directly observed therapy, short course (DOTS) was introduced, TB continues to rise worldwide. The introduction of selected multiple drug resistant TB treatment programmes, "DOTS-Plus", although important, also focuses on therapy for active TB. HIV endemic countries in particular have experienced tremendous increases in TB despite having DOTS programmes. A critical review of recent epidemiological data and computer models shows that the present international strategy of concentrating on providing treatment for smear positive TB, DOTS and DOTS-Plus, is likely to have only a modest impact on population based TB control. Effective global TB control will require strategies that go beyond relying on treatment of people with active disease.

Entities:  

Mesh:

Year:  2004        PMID: 15365106      PMCID: PMC1763333          DOI: 10.1136/jech.2003.008664

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  37 in total

1.  The Russian equation: an evolving paradigm in tuberculosis control.

Authors:  M E Kimerling
Journal:  Int J Tuberc Lung Dis       Date:  2000-12       Impact factor: 2.373

2.  The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru.

Authors:  P G Suárez; C J Watt; E Alarcón; J Portocarrero; D Zavala; R Canales; F Luelmo; M A Espinal; C Dye
Journal:  J Infect Dis       Date:  2001-07-18       Impact factor: 5.226

3.  Evolution of WHO policies for tuberculosis control, 1948-2001.

Authors:  M C Raviglione; A Pio
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

Review 4.  Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Authors:  R Gupta; M C Raviglione; M A Espinal
Journal:  Int J Tuberc Lung Dis       Date:  2001-12       Impact factor: 2.373

5.  A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.

Authors:  D L Cohn; B J Catlin; K L Peterson; F N Judson; J A Sbarbaro
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

6.  Microscopic evaluation of sputum specimens submitted for Mycobacterium tuberculosis culture.

Authors:  J L Isaac-Renton; B B Puselja; E A Allen; S Grzybowski; W A Black
Journal:  Am J Clin Pathol       Date:  1985-09       Impact factor: 2.493

7.  Evaluation of tuberculosis control policies using computer simulation.

Authors:  T F Brewer; S J Heymann; G A Colditz; M E Wilson; K Auerbach; D Kane; H V Fineberg
Journal:  JAMA       Date:  1996-12-18       Impact factor: 56.272

8.  A controlled trial of community-wide isoniazid prophylaxis in Alaska.

Authors:  G W Comstock; S H Ferebee; L M Hammes
Journal:  Am Rev Respir Dis       Date:  1967-06

9.  Tuberculosis 2000-2010: control, but not elimination.

Authors:  C Dye
Journal:  Int J Tuberc Lung Dis       Date:  2000-12       Impact factor: 2.373

10.  Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment.

Authors:  T C Kim; R S Blackman; K M Heatwole; T Kim; D F Rochester
Journal:  Am Rev Respir Dis       Date:  1984-02
View more
  11 in total

1.  Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis.

Authors:  Jia Yao Phuah; Joshua T Mattila; Philana L Lin; JoAnne L Flynn
Journal:  Am J Pathol       Date:  2012-06-19       Impact factor: 4.307

2.  Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality.

Authors:  Philippe Glaziou; Katherine Floyd; Eline L Korenromp; Charalambos Sismanidis; Ana L Bierrenbach; Brian G Williams; Rifat Atun; Mario Raviglione
Journal:  Bull World Health Organ       Date:  2011-05-31       Impact factor: 9.408

3.  Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent.

Authors:  Pieter W Uys; Robin Warren; Paul D van Helden; Megan Murray; Thomas C Victor
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

4.  Effect of a hospital-based case management approach on treatment outcome of patients with tuberculosis.

Authors:  Rong-Luh Lin; Fung-J Lin; Chien-Liang Wu; Ming-Jen Peng; Pei-Jan Chen; Hsu-Tah Kuo
Journal:  J Formos Med Assoc       Date:  2006-08       Impact factor: 3.282

5.  CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis.

Authors:  Bikul Das; Suely S Kashino; Ista Pulu; Deepjyoti Kalita; Vijay Swami; Herman Yeger; Dean W Felsher; Antonio Campos-Neto
Journal:  Sci Transl Med       Date:  2013-01-30       Impact factor: 17.956

6.  Biomarkers of oxidative stress and personalized treatment of pulmonary tuberculosis: emerging role of gamma-glutamyltransferase.

Authors:  Etienne Mokondjimobe; Benjamin Longo-Mbenza; Jean Akiana; Ulrich Oswald Ndalla; Regis Dossou-Yovo; Joseph Mboussa; Henri-Joseph Parra
Journal:  Adv Pharmacol Sci       Date:  2012-05-07

7.  Disintegrated care: the Achilles heel of international health policies in low and middle-income countries.

Authors:  Jean-Pierre Unger; Pierre De Paepe; Patricia Ghilbert; Werner Soors; Andrew Green
Journal:  Int J Integr Care       Date:  2006-09-18       Impact factor: 5.120

8.  Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients.

Authors:  Getnet Yimer; Getachew Aderaye; Wondwossen Amogne; Eyasu Makonnen; Eleni Aklillu; Lars Lindquist; Lawrence Yamuah; Beniyam Feleke; Abraham Aseffa
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

9.  National guidelines not always followed when diagnosing smear-negative pulmonary tuberculosis in patients with HIV in Botswana.

Authors:  Taurayi A Tafuma; Rosemary J Burnett; Diana Huis In 't Veld
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  Bringing state-of-the-art diagnostics to vulnerable populations: The use of a mobile screening unit in active case finding for tuberculosis in Palawan, the Philippines.

Authors:  Fukushi Morishita; Anna Marie Celina Gonzales Garfin; Woojin Lew; Kyung Hyun Oh; Rajendra-Prasad Yadav; Janeth Cuencaho Reston; Lenie Lucio Infante; Maria Rebethia Crueldad Acala; Dean Lim Palanca; Hee Jin Kim; Nobuyuki Nishikiori
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.